PremiumThe FlyBio-Rad now sees non-GAAP revenue for FY down 1% to up 1.5% Bio-Rad reports Q1 EPS $2.54, consensus $1.78 Is BIO a Buy, Before Earnings? PremiumCompany AnnouncementsBio-Rad Laboratories Reports 2024 Earnings and Strategic Plans Bio-Rad reports Q4 adjusted EPS $2.90, consensus $2.88 Bio-Rad sees FY25 currency neutral revenue growth 1.5%-3.5% PremiumThe FlyBio-Rad price target raised to $469 from $446 at RBC Capital Bio-Rad price target raised to $450 from $400 at Citi Bio-Rad Laboratories Reports Q3 2024 Earnings Growth